INTRODUCTION P
OLYUNSATURATED FATTY ACIDS (PUFAs) have been shown to improve insulin sensitivity, lower triglycerides, increase plasma HDL and decrease hepatic lipogenesis (Storlien et al., 1987; Nestel, 1990; Jump and Clarke, 1999) . The mechanism by which PUFAs regulate lipid metabolism has been extensively studied in recent years. Several transcription factors, including the nuclear receptors peroxisome proliferator-activated receptor (PPAR␣) and the liver X receptor (LXR), have been demonstrated to mediate biological effects of PUFAs (Gottlicher et al., 1992; Desvergne and Wahli, 1999; Guerre-Millo et al., 2000; Ou et al., 2001) . PUFAs are PPAR␣ agonists, and activation of PPAR␣ results in an increased lipid oxidation and decreased lipid synthesis (Ren et al., 1997; Pan, et al., 2000; Dallongeville et al., 2001) . PUFAs have recently been identified as LXR antagonists that suppress LXR agonist-induced gene expression (Kim et al., 1999; Xu et al., 1999; Yahagi et al., 1999; Hannah et al., 2001) . For example, PUFAs decrease expression of the sterol regulatory element (SRE)-binding proteins-1c (SREBP-1c) by inhibition of LXR binding to LXR response elements (Guerre-Millo et al., 2000; Ou et al., 2001; Yoshikawa et al., 2002) . Suppression of SREBP-1c expression by PUFAs may contribute to reduced lipid synthesis. In the present study, we report that PUFAs are selective modulators of farnesoid X receptor (FXR), and that they regulate expression of FXR targets in a gene-specific fashion.
FXR is a nuclear receptor for bile acids and controls expression of genes whose products are critically important in bile acid and cholesterol homeostasis (Makishima et al., 1999; Parks et al., 1999; Wang et al., 1999; Tu et al., 2000; Russell, 2003) . FXR controls bile acid synthesis by inhibiting expression of cholesterol 7␣-hydroxylase (Bramlett et al., 2000; Chiang et al., 2000; Goodwin et al., 2000; Lu et al., 2000) and sterol 12 ␣-hydroxylase (Zhang and Chiang 2001) and controls bile acid transportation by regulating expression of critical hepatic bile acid and lipid transporters such as bile salt export pump (BSEP) (Ananthanarayanan et al., 2001; Yu et al., 2002) , the Na ϩ /taurocholate cotransporting polypeptide (Denson et al., 2001) , the phospholipid transporter MDR3 and MRP2 (Kast et al., 2002) . In addition, FXR controls expression of the intestinal bile acid binding protein (Grober et al., 1999) , phospholipid transfer protein (Urizar et al., 2000) , apolipoproteins A-I (Claudel et al., 2002) , C-II (Kast et al., 2001) , and CIII (Claudel et al., 2003) . We have recently reported that FXR activates expression of human kininogen gene whose products have critical roles in vasodilation and anticoagulation .
In this study, we first provide evidence showing that PUFAs bind to FXR and decrease FXR agonist-induced coactivator association in cell-free systems. We then use two FXR targets, BSEP and kininogen, as tools to examine whether PUFAs can regulate FXR target expression in hepatic cells. Although both genes are robustly induced by FXR agonists in HepG2 cells, PUFAs displayed opposite regulation on their expression. PUFAs enhanced FXR agonist-induced BSEP expression but decreased FXR agonist-induced kininogen expression. These effects are not mediated through PPAR␣ activities since a selective synthetic PPAR␣ agonist did not show significant effects on expression of these two genes. The properties of PUFAs including the FXR antagonist activities in coactivator association, enhancement of BSEP expression and suppression of kininogen expression closely resemble those of guggulsterones, previously reported as selective bile acid receptor modulators (SBARM) (Cui et al., 2003) . Taken together, results of this study suggest that PUFAs are the endogenous selective modulators of FXR that regulate expression of FXR targets in a gene-specific fashion.
MATERIALS AND METHODS

Reagents
The following reagents were obtained from Invitrogen: tissue culture media of DME and Optimem I; regular fetal bovine serum (FBS) and charcoal striped-FBS (CS-FBS); TRIZOL reagents; chenodeoxycholate (CDCA) and Z-guggulsterone was obtained from Steraloids, Inc. (Newport, RI). Fatty acids were from Sigma (St. Louis, MO). GW4064 was synthesized at Merck (Rahway, NJ). TaqMan reagents for cDNA synthesis and real-time PCR, and TaqMan oligonucleotide primers and probes for human BSEP, kininogen, CPT-1, and 18S RNA were purchased from Applied Biosystems (Foster City, CA). SA/XL665 and (Eu)K were from CIS Biointernational (Bagnols-sur-Ceze, France) and Packard Instrument Co. (Meriden, CT). Goat anti-GST antibody and Protein A-Yttrium Silicate SPA beads were purchased from Amersham Pharmacia Biotech (Lake Forest, IL).
FXR scintillation proximity binding assay (SPA)
The assay was performed in 96-well microtiter plates in a total volume of 100 l/well including 100 ng GST-hFXR fusion protein, goat anti-GST antibody (1:400-fold dilution), 250 g Protein A-Yttrium Silicate SPA beads and a 3 H-labeled FXR radioligand (2 nM final concentration) in an assay buffer consisting of 10 mM Tris-HCl, pH 7.2, 1 mM EDTA, 10% glycerol, 10 mM sodium molybdate, 1 mM DTT, 2 g/ml benzamidine, 0.5 mM PMSF, and 0.05% dry milk. Plates were incubated at 4°C for 16 h with shaking. Radioactivity was quantified in a Packard Topcount scintillation counter. Each value represents the mean Ϯ SD of three determinations.
FXR coactivator association assays
Preparation of GST-FXR-LBD fusion protein from Escherichia coli strain BL21 and protocols for a homogeneous time-resolved fluorescence (HTRF)-based interaction of GST-FXR-LBD with the coactivator SRC-1 were described previously . Reactions for compound antagonist activities included 9 M CDCA (an FXR agonist) in the assay buffer.
Treatment of HepG2 cells for gene expression
HepG2 cells were maintained in DMEM containing 10% FBS, 1% Pen/Strep, 1 mM sodium pyruvate, and 5 mM HEPES. For determination of gene-specific expression by TaqMan analysis, cells were seeded in six-well plates at a density of 1 million cells/well in DMEM containing 10% FBS, 1% Pen/Strep, and 25 mM HEPES. Twenty-four hours after seeding, cells were treated with various concentrations of compounds in DMEM containing 0.5% CS-FBS, 1% Pen/Strep, and 25 mM HEPES for 24 h.
RNA isolation and real-time quantitative PCR
Total RNA was extracted from the cultured cells using the TRIZOL reagent according to the manufacturer's instructions. Reverse transcription reactions and TaqMan-PCRs were performed according to the manufacturer's instructions (Applied ZHAO ET AL. 520
FIG. 1. Binding affinity of fatty acids on human FXR-LBD.
The FXR scintillation proximity binding assay (SPA) was performed in 96-well microtiter plates as described in Materials and Methods. The IC 50 value for each fatty acid is indicated. Each value represents the mean Ϯ SD of three determinations. Biosystems) (Norwalk, CT). Sequence-specific amplification was detected with an increased fluorescent signal of FAM (reporter dye) during the amplification cycles. Amplification of human 18S RNA was used in the same reaction of all samples as an internal control. Gene-specific mRNA was subsequently normalized to 18S RNA. Levels of human BSEP, kininogen, and CPT-1 mRNA was expressed as fold difference of compound-treated cells against DMSO-treated cells.
TaqMan oligonucleotide primers and probes for BSEP and kininogen were previously described . Sequences of CPT-1 primers/probe are: forward primer (CGTCTTTTGGGATCCACGATT), probe (6FAM-TTAAACATCCGCTCCCACTGAGCGG-TAMRA), and reverse primer (TGTGCTGGATGGTGTCTGTCTC).
RESULTS
PUFAs bind to FXR
Polyunsaturated fatty acids (PUFAs) were previously identified as agonist ligands of PPAR␣ and antagonist ligands of LXR. To determine whether PUFAs are also ligands of FXR, three representative PUFAs, arachidonic acid (AA, 20:4), docosahexaenoic acid (DA, 22:6), and linolenic acid (LA, 18:3) were first evaluated in a FXR SPA binding assay. Figure 1 shows that all three PUFAs bound to the FXR ligand-binding domain (LBD) with an affinity ranging from 1.5 to 3.5 M. Two saturated fatty acids, stearic acid (SA, 18:0) and palmitic acid (PA, 16:0), had no significant binding activities on FXR-LBD (Fig. 1) . These results indicate that only polyunsaturated but not saturated fatty acids bind to FXR.
PUFAs are FXR antagonists in a coactivator association assay
A homogeneous time-resolved fluorescence-based FXR coactivator association assay was used to assess FXR ago-
FIG. 2.
Effects of fatty acids on interaction of FXR-LBD with coactivator SRC-1. Purified GST-FXR-LBD (4 nM) was incubated with 2 nM anti-GST-(Eu)K, 10 nM biotin-SRC-1 (568-780), 20 nM SA/XL665, and various concentrations of fatty acids in the presence of 9 M CDCA. The mixture was incubated overnight at 4°C. The fluorescent signal was measured, and results were calculated as described in Materials and Methods. The IC 50 value for each fatty acid is indicated. Each value represents the mean Ϯ SD of three determinations.
FIG. 3.
Enhancement of PUFAs on FXR agonist-induced BSEP expression. HepG2 cells at a density of one million cells/well in six-well plates were treated with various concentrations of fatty acids in the presence of 100 nM GW4064 for 24 h. Total RNA was prepared and BSEP mRNA was analyzed by TaqMan-PCR as described in Materials and Methods. Results are normalized as fold of control (treated cells versus vehicle), and data are the mean Ϯ SD of three determinations. nism/antagonism of PUFAs in the cell-free system. This assay measured ligand-dependent association of FXR with the coactivator SRC-1 . FXR agonists such as CDCA and GW4064 robustly induce the interaction between FXR and SRC-1 . PUFAs alone, however, failed to activate FXR (data not shown). Rather, all three PUFAs, AA, DA, and LA, decreased the activation of FXR caused by CDCA in a dose-dependent fashion with an IC50 of 1.0, 0.9, and 4.7 M, ZHAO ET AL. 522
FIG. 4.
Effects of PUFAs on kininogen expression. HepG2 cells at a density of one million cells/well in six-well plates were treated with various concentrations of fatty acids in the presence of 100 nM GW4064 for 24 h. Total RNA was prepared and kininogen mRNA was analyzed by TaqMan-PCR as described in Materials and Methods. Results are normalized as fold of control (treated cells versus vehicle), and data are the mean Ϯ SD of three determinations.
FIG. 5.
Effects of PUFAs on CPT-1 expression. HepG2 cells at a density of one million cells/well in six-well plates were treated with various concentrations of fatty acids for 24 h. Total RNA was prepared and CPT-1 mRNA was analyzed by TaqMan-PCR as described in Materials and Methods. Results are normalized as fold of control (treated cells versus vehicle), and data are the mean Ϯ SD of three determinations. respectively (Fig. 2) . The two saturated fatty acids SA and PA did not show FXR antagonist in the coactivator association assay.
PUFAs enhance FXR agonist-induced endogenous expression of BSEP
BSEP is the major hepatic bile acid transporter that mediates the transport of bile acids across the canalicular membrane (Hofmann, 1999; Kullak-Ublick et al., 2000; Lecureur et al., 2000) . BSEP deficiencies in humans result in progressive familial intrahepatic cholestasis type 2 (Strautnieks et al., 1998) . Recent studies have shown that BSEP transcription is strongly activated by FXR via a FXR response element (FXRE) in the BSEP promoter (Ananthanarayanan et al., 2001) . Since PUFAs are FXR antagonists in the coactivator association assay, we asked whether PUFAs would decrease FXR agonist-induced BSEP expression in HepG2 cells. To answer this question, HepG2 cells were treated with fatty acids in the presence of a potent and specific synthetic FXR agonist GW4064 (Maloney et al., 2000) , and BSEP mRNA was quantified by real-time PCR (TaqMan). Consistent with previous results , GW4064 strongly induced BSEP expression in HepG2 cells with an approximate 50-80-fold induction at 100 nM (Fig. 3) . Treatment of HepG2 cells with PUFAs did not inhibit but enhanced the GW4064-induced BSEP expression to 150-200-fold (Fig. 3) . This enhancement was in a dose-dependent fashion with a maximum of two-to three-fold that induced by GW4064 alone (Fig.  3) . The two saturated fatty acids SA and PA showed no significant effects on GW4064-induced BSEP expression (Fig. 3) .
In the absence of an FXR agonist, the three PUFAs did not significantly change BSEP expression in HepG2 cells (data not shown).
PUFAs decrease endogenous expression of kininogen
To further determine whether PUFAs also influence expression of another FXR target whose expression is greatly transactivated by FXR, we studied the effect of PUFAs on kininogen mRNA. We have recently shown that kininogen expression is robustly increased by FXR agonists in HepG2 cells . Consistently, in this study treatment with GW4064 also increased kininogen mRNA by approximate 100-fold (Fig.  4) . However, in contrast to the observation on BSEP expression, treatment with each of the three PUFAs effectively decreased GW4064-induced kininogen mRNA in a dose-dependent manner (FIg. 4) . The saturated fatty acids SA and PA did not change kininogen expression (Fig. 4) . Again, in the absence of GW4064, PUFAs alone did not change kininogen mRNA in these cells (data not shown).
FIG. 6.
Effects of a synthetic PPAR␣ ligand on BSEP and kininogen expression. HepG2 cells at a density of one million cells/well in six-well plates were treated with various concentrations of a synthetic PPAR␣ ligand in the presence of 100 nM GW4064 for 24 h. Total RNA was prepared and BSEP mRNA (A) or kininogen mRNA (B) was analyzed by TaqMan-PCR as described in Materials and Methods. Results are normalized as fold of control (treated cells versus vehicle), and data are the mean Ϯ SD of three determinations.
FIG. 7.
Effects of GS on kininogen expression. HepG2 cells at a density of one million cells/well in six-well plates were treated with various concentrations of GS in the presence of 100 nM GW4064 for 24 h. Total RNA was prepared and kininogen mRNA was analyzed by TaqMan-PCR as described in Materials and Methods. Results are normalized as fold of control (treated cells versus vehicle), and data are the mean Ϯ SD of three determinations.
PUFAs increase CPT-1 expression
PUFAs activate PPAR␣, resulting in an increase in lipid oxidation and decrease in lipid synthesis by coordinately regulating expression of PPAR␣ targets (Ren et al., 1997; Pan et al., 2000; Dallongeville et al., 2001) . We determined whether in HepG2 cells the same set of PUFAs also increase expression of CPT-1, a known target of PPAR␣. As demonstrated in Figure 5 , all three PUFAs robustly increased CPT-1 mRNA in a dose-dependent manner, while the two saturated fatty acids SA and PA had virtually no effects. These data confirm that this set of PUFAs were able to induce the PPAR␣ target CPT-1 expression in HepG2 cells.
A selective ligand of PPAR␣ does not regulate expression of BSEP and kininogen
To eliminate the possibility that the regulation of BSEP and kininogen expression by PUFAs is attributed to PPAR␣ rather than FXR activities, HepG2 cells were also treated with a potent and selective synthetic PPAR␣ ligand (compound 1 in Lawrence et al., 2001 ). This compound was previously shown to induce CPT-1 expression in HepG2 cells (Lawrence et al., 2001 ). In our experiment system, we also observed a similar induction of CPT-1 expression for this compound in HepG2 cells (data not shown). However, this compound neither increased BSEP mRNA nor decreased kininogen mRNA in the presence of the FXR agonist GW4064 (Fig. 6A and 6B ). Taken together, these data suggest that PUFAs are selective modulators of FXR that regulate expression of FXR targets in a gene-specific fashion.
DISCUSSION
PUFAs have been shown to have many beneficial effects including improvement of plasma lipid profiles, improvement of insulin sensitivity, and decrease of plasma triglycerides and hepatic lipogenesis (Storlien et al., 1987; Nestel, 1990; Jump and Clarke, 1999) . The molecular mechanisms for these beneficial effects are not fully understood, although the nuclear receptors PPAR␣ and LXR have been proposed to mediate some of these effects. PUFAs are agonists of PPAR␣ and antagonists of LXR. In this study, we show that PUFAs are FXR ligands that regulate expression of FXR targets in a gene-specific fashion. Thus, the activities of PUFAs on FXR may also contribute to their beneficial effects on lipid and glucose metabolism.
We have previously reported that the natural product, guggulsterone (GS), acted as an FXR antagonist in a coactivator association assay but enhanced FXR agonist-induced BSEP expression in HepG2 cells (Cui et al., 2003) . This study demonstrates that PUFAs bound to FXR and also behaved as FXR antagonists in the coactivator association assay. Furthermore, in HepG2 cells, PUFAs enhanced FXR agonist-induced BSEP expression but decreased FXR agonist-induced kininogen mRNA. In the previous study with GS, we did not examine whether GS also regulated kininogen expression. To complete the comparison of PUFA and GS, we also evaluated Z-GS in regulation of kininogen expression in this study. Similar to PUFAs, Z-GS dose dependently decreased GW4064-induced kininogen mRNA (Fig. 7) . Thus, PUFAs and GS have a similar pattern of FXR activities and a similar pattern of regulation of BSEP and kininogen, suggesting that PUFAs and GS may belong to the same unique class of FXR ligands.
To rule out the possibility that the regulation of BSEP and kininogen by PUFAs resulted from the PPAR␣ activity, we tested a selective and potent PPAR␣ ligand on expression of these two genes. Different from PUFAs, this PPAR␣ ligand had no effects on expression of BSEP or kininogen (Fig. 6A and B) .
The results of this study suggest that PUFAs are endogenous and selective bile acid receptor modulators that specifically regulate expression of certain FXR targets. These activities on FXR may contribute to metabolic effects of PUFAs since FXR plays a critical role in lipid metabolisms. Our findings further enhance the understanding of FXR function, and also implicate another layer of complexity in PUFA-mediated signaling pathways.
